Oncology
HER2 Breast Cancer: Treatment Confidence Starts with Clarity.
KEEP learned from 29 people with confirmed breast cancer in May 2026, many close to a treatment decision. The defining tension is biomarker clarity: 52% had no confirmed HER2 test in the past year, and 41% could not report a clear HER2 status. Patients want decision confidence, not more information, with 66% focused on confirming they are on the right treatment. The report outlines how to build a clear path from status to decision.
Patient RecruitmentPatient IntelligencePatient Experience
Key Highlights
52% had no confirmed HER2 test in the past year
66% want to confirm they are on the right treatment
86% make evidence-led health decisions
Overview
29 confirmed breast cancer patients reveal that unclear or outdated HER2 status stands between them and confident treatment decisions.
